| abstract |
Disclosed herein are methods for controlling the activity of hypoxia-inducible transcription factor-1α (HIF-1α) and diseases, disorders or syndromes associated therewith - especially peripheral vascular disease (PVD), coronary artery disease (CAN), heart failure , ischemia and anemia - method. Also disclosed are pharmaceutical compositions comprising HIF-la prolyl hydroxylase inhibitors useful for treating diseases, disorders and/or syndromes associated with HIF-la activity. |